Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 28:4:29.
doi: 10.21037/tbcr-23-40. eCollection 2023.

A clinical perspective on oncoplastic breast conserving surgery

Eva Heeling  1 , Annemiek K E van Hemert  1 , Marie-Jeanne T F D Vrancken Peeters  1   2
Affiliations
Review

A clinical perspective on oncoplastic breast conserving surgery

Eva Heeling et al. Transl Breast Cancer Res. .

Abstract

Breast conserving surgery (BCS) plus radiation treatment is the favored alternative for mastectomy in patients with breast cancer. To allow for breast conservation in patients with large invasive tumors and poor response to neoadjuvant systemic treatment (NST) or patients with extensive ductal carcinoma in situ (DCIS), oncoplastic breast conserving surgery (OPBCS) techniques are introduced. OPBCS allows for breast conservation in a selective group of breast cancer patients who initially would have been treated with mastectomy due to the unfavorable tumor-to-breast ratio. With OPBCS, the oncological tumor excision is combined with plastic surgical breast conservation techniques without compromising oncological safety and maintaining aesthetic outcomes by preserving the shape of the breast. OPBCS should however not be applied to all breast cancer patients and the selection of patients who benefit from OPBCS and the timing of OPBCS are best discussed in a multidisciplinary team (MDT). Caution is required in patients with higher risk of positive margins [e.g., multifocal breast cancer, invasive lobular carcinoma (ILC), larger tumors and DCIS]. In these patients, delayed OPBCS is recommended to facilitate re-excision and maintain excellent breast conserving rates. Despite proven benefits in selected patients, the increase in the adoption of OPBCS is relatively low. This article provides a clinical perspective on OPBCS.

Keywords: Breast cancer; breast conserving surgery (BCS); breast reconstruction; oncoplastic breast conserving surgery (OPBCS).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tbcr.amegroups.com/article/view/10.21037/tbcr-23-40/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Patient A with usage of OPBCS. A 69-year-old patient, with a screen detected right-sided cT1N0M0, invasive lobular carcinoma with extensive DCIS (A: mammography). She underwent primary OPBCS (volume displacement) using a reduction technique following the Wise-pattern (B: per-operative, C: postoperative). OPBCS, oncoplastic breast conserving surgery; DCIS, ductal carcinoma in situ.
Figure 2
Figure 2
Patient B with usage of OPBCS. A 51-year-old patient, with a left-sided breast tumor: stage cT2mN1M0, HR-positive/HER2-negative of no special type with extensive DCIS. Imaging was performed before (A) and after (B) four cycles of doxorubicine and cyclofosfamide combined with 12 times paclitaxel, showing a radiological complete response. She underwent OPBCS (volume replacement) by use of TDAP flap technique due to extensive DCIS in the left breast (C). OPBCS, oncoplastic breast conserving surgery; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; DCIS, ductal carcinoma in situ; TDAP, thoracodorsal artery perforator.
Figure 3
Figure 3
Two-step approach of OPBCS. OPBCS* = level 2 oncoplastic surgery using either volume displacement or volume replacement techniques. OPBCS, oncoplastic breast conserving surgery; DCIS, ductal carcinoma in situ; s-BCS, standard breast conserving surgery.
See this image and copyright information in PMC

References

    1. Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg 2015;220:1063-9. 10.1016/j.jamcollsurg.2015.02.011 - DOI - PubMed
    1. van der Noordaa MEM, Ioan I, Rutgers EJ, et al. Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience. Ann Surg Oncol 2021;28:7383-94. 10.1245/s10434-021-09865-4 - DOI - PubMed
    1. Puig CA, Hoskin TL, Day CN, et al. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study. Ann Surg Oncol 2017;24:1242-50. 10.1245/s10434-016-5733-y - DOI - PubMed
    1. Spronk PER, Volders JH, van den Tol P, et al. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit. Eur J Surg Oncol 2019;45:110-7. 10.1016/j.ejso.2018.09.027 - DOI - PubMed
    1. van Bommel A, Spronk P, Mureau M, et al. Breast-Contour-Preserving Procedure as a Multidisciplinary Parameter of Esthetic Outcome in Breast Cancer Treatment in The Netherlands. Ann Surg Oncol 2019;26:1704-11. 10.1245/s10434-019-07265-3 - DOI - PMC - PubMed